BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26844509)

  • 1. Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer.
    Lee SG; Ho J; Choi JB; Kim TH; Kim MJ; Ban EJ; Lee CR; Kang SW; Jeong JJ; Nam KH; Jung SG; Jo YS; Lee J; Chung WY
    Medicine (Baltimore); 2016 Feb; 95(5):e2692. PubMed ID: 26844509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node ratio predicts recurrence in papillary thyroid cancer.
    Schneider DF; Mazeh H; Chen H; Sippel RS
    Oncologist; 2013; 18(2):157-62. PubMed ID: 23345543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal value of lymph node ratio and metastatic lymph node size to predict risk of recurrence in pediatric thyroid cancer with lateral neck metastasis.
    Back K; Kim TH; Lee J; Kim JS; Choe JH; Oh YL; Cho A; Kim JH
    J Pediatr Surg; 2023 Mar; 58(3):568-573. PubMed ID: 35973863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node ratio predicts recurrence in pediatric papillary thyroid cancer.
    Rubinstein JC; Dinauer C; Herrick-Reynolds K; Morotti R; Callender GG; Christison-Lagay ER
    J Pediatr Surg; 2019 Jan; 54(1):129-132. PubMed ID: 30361076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
    Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
    Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of lymph node yield and lymph node ratio in papillary thyroid carcinoma.
    Vas Nunes JH; Clark JR; Gao K; Chua E; Campbell P; Niles N; Gargya A; Elliott MS
    Thyroid; 2013 Jul; 23(7):811-6. PubMed ID: 23373961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restratification of survival prognosis of N1b papillary thyroid cancer by lateral lymph node ratio and largest lymph node size.
    Kim HI; Kim TH; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim YN; Kim H; Ahn HS; Kim K; Kim SW; Chung JH
    Cancer Med; 2017 Oct; 6(10):2244-2251. PubMed ID: 28857489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma.
    Ryu IS; Song CI; Choi SH; Roh JL; Nam SY; Kim SY
    Ann Surg Oncol; 2014 Jan; 21(1):277-83. PubMed ID: 24006096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the role of central lymph node ratio in predicting recurrence in N1a low-to-intermediate risk papillary thyroid carcinoma.
    Ma T; Cui J; Shi P; Liang M; Song W; Zhang X; Wang L; Shi Y
    Front Endocrinol (Lausanne); 2023; 14():1158826. PubMed ID: 37790606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Recurrence of Small Papillary Thyroid Cancer and Its Risk Factors in a Korean Multicenter Study.
    Hwangbo Y; Kim JM; Park YJ; Lee EK; Lee YJ; Park DJ; Choi YS; Lee KD; Sohn SY; Kim SW; Chung JH; Lim DJ; Kim MH; Kim MJ; Jo YS; Shong MH; Koong SS; Hahm JR; Jung JH; Yi KH
    J Clin Endocrinol Metab; 2017 Feb; 102(2):625-633. PubMed ID: 27732329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
    Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
    Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for level V metastasis in patients with N1b papillary thyroid cancer.
    Kang JG; Choi JE; Kang SH
    World J Surg Oncol; 2022 Sep; 20(1):327. PubMed ID: 36180912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management.
    Chéreau N; Buffet C; Trésallet C; Tissier F; Leenhardt L; Menegaux F
    Surgery; 2016 Mar; 159(3):755-62. PubMed ID: 26435440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma.
    Kang IK; Kim K; Park J; Bae JS; Kim JS
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node ratio in lateral neck is an independent risk factor for recurrence-free survival in papillary thyroid cancer patients with positive lymph nodes.
    Luo Z; Hei H; Qin J; Zheng C; Gong W
    Endocrine; 2022 Dec; 78(3):484-490. PubMed ID: 36018538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
    Wu MH; Shen WT; Gosnell J; Duh QY
    Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of the Number of Harvested Lymph Nodes and Cut-Off for Lymph Node Ratio in the Prognosis of Stage II and III Colorectal Cancer Patients.
    Li Destri G; Barchitta M; Pesce A; Latteri S; Bosco D; Di Cataldo A; Agodi A; Puleo S
    J Invest Surg; 2019 Jan; 32(1):1-7. PubMed ID: 28972442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying risk factors of lateral lymph node recurrence in clinically node-negative papillary thyroid cancer.
    Ryu YJ; Kang SJ; Cho JS; Yoon JH; Park MH
    Medicine (Baltimore); 2018 Dec; 97(51):e13435. PubMed ID: 30572443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node ratio as a tool to stratify patients with N1b papillary thyroid cancer.
    Luo Z; Hei H; Qin J; Zheng C; Gong W; Zhou B
    Langenbecks Arch Surg; 2023 Aug; 408(1):315. PubMed ID: 37584830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome.
    Sapuppo G; Palermo F; Russo M; Tavarelli M; Masucci R; Squatrito S; Vigneri R; Pellegriti G
    J Endocrinol Invest; 2017 Dec; 40(12):1355-1363. PubMed ID: 28646475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.